Cytokinetics Inc (NASDAQ:CYTK): Mark Lampert’s Biotechnology Value Fund LP filed an amended 13D.
You can check out Biotechnology Value Fund LP’s latest holdings and filings here.
Please follow Biotechnology Value Fund LP (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Biotechnology Value Fund LP or update its stock holdings.
Follow Mark Lampert's Biotechnology Value Fund / BVF Inc
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund | 0 | 0 | 2,691,120 | 2,691,120 | 5.0% | |
| Biotechnology Value Fund II | 0 | 0 | 1,718,193 | 1,718,193 | 3.2% | |
| Biotechnology Value Trading Fund OS | 0 | 0 | 459,326 | 459,326 | Less than 1% | |
| BVF Partners OS Ltd | 0 | 0 | 459,326 | 459,326 | Less than 1% | |
| BVF Partners | 0 | 0 | 5,427,313 | 5,427,313 | 10.1% | |
| BVF Inc | 0 | 0 | 5,427,313 | 5,427,313 | 10.1% | |
| Mark N. Lampert | 0 | 0 | 5,427,313 | 5,427,313 | 10.1% |
Page 1 of 13 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c),
AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 6)1
| Cytokinetics, Incorporated |
| (Name of Issuer) |
| Common Stock, $0.001 par value per share |
| (Title of Class of Securities) |
| 23282W605 |
| (CUSIP Number) |
| November 28, 2017 |
| (Date of Event Which Requires Filing of this |
Check the appropriate box
to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☒ | Rule 13d-1(c) |
| ☐ | Rule 13d-1(d) |
1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
